Combinatorial ablation and immunotherapy

Combinatorial ablation and immunotherapy is an oncological treatment that combines various tumor-ablation techniques with immunotherapy treatment.[1][2][3][4] Combining ablation therapy of tumors with immunotherapy enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.[2][3] Various ablative techniques are utilized including cryoablation, radiofrequency ablation, laser ablation, photodynamic ablation, stereotactic radiation therapy, hyperthermia therapy, HIFU.[5][6] [7] [8][9][10] Thus, combinatorial ablation of tumors and immunotherapy is a way of achieving autologous, in-vivo tumor lysate vaccine and treat metastatic disease.

Mechanism of action

Partially or entirely ablating primary or secondary metastatic tumors induces necrosis of tumor cells, resulting in the release of antigens and presentation of antigens to the immune system. The released tumor antigens help activate anti-tumor T cells, which can destroy remaining malignant cells in local and distant tumors. Combining immunotherapy (ie: checkpoint inhibitors, CAR-T cell therapy) and vaccine adjuvants (ie: interferon, saponin) with ablation synergizes the immune reaction, and can treat metastatic disease with curative intent. [3] [11][12] [13] [14][15]

Ablation therapies

Various local ablation therapies exist to induce necrosis of tumor cells and release tumor antigens for an immunological response, this is combined with immunotherapy:

See also

References

  1. Dupuy; et al. (2014). "Thermal ablation of tumours: biological mechanisms and advances in therapy". Nature Reviews Cancer. 14 (3): 199–208. PMID 24561446. doi:10.1038/nrc3672.
  2. 1 2 "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?". 2015.
  3. 1 2 3 "Immunotherapy could transform systemic power of locoregional IO treatments". 2016.
  4. Dranoff, Glenn (2016). Cancer Immunology and Immunotherapy. p. 218. ISBN 9783642141362.
  5. Prof. Yona Keisari. "Development of Cancer Treatments Integrating Radiotherapy or Electrochemical Ablation and Immunotherapy".
  6. Ito, A; Tanaka, K; Kondo, K; Shinkai, M; Honda, H; Matsumoto, K; Saida, T; Kobayashi, T (2003). "Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma". Cancer science. 94 (3): 308–13. PMID 12824927.
  7. Xiaoming Yang (2016). "Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy". Oncotarget. doi:10.18632/oncotarget.11346.
  8. Braiden, V; Ohtsuru, A; Kawashita, Y; Miki, F; Sawada, T; Ito, M; Cao, Y; Kaneda, Y; Koji, T; Yamashita, S (2000). "Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter". Human Gene Therapy. 11 (18): 2453–63. PMID 11119417. doi:10.1089/10430340050207948.
  9. Takeda, Tsutomu; Takeda, Takashi (2016). "Combination by Hyperthermia and Immunotherapy: DC Therapy and Hyperthermia": 319. ISBN 978-981-10-0717-0. doi:10.1007/978-981-10-0719-4_30. |chapter= ignored (help)
  10. "A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination." (PDF). Austin Oncol Case Rep. 2017.
  11. "Cryo-thermal therapy elicits potent anti-tumor immunity.". 2015.
  12. Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.Sabel (2005). "Immunologic response to cryoablation of breast cancer". Gland Surg. 3 (2): 88–93. PMC 4115762Freely accessible. PMID 25083502. doi:10.3978/j.issn.2227-684X.2014.03.04 (inactive 2017-05-16).
  13. "Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity.". 2005.
  14. Mehta, Amol; Oklu, Rahmi; Sheth, Rahul A. (2016). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response". Gastroenterol Res Pract. 2016: 1–11. doi:10.1155/2016/9251375.
  15. "Nanoparticle-mediated hyperthermia in cancer therapy.". 2012.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.